NCT02419937View on ClinicalTrials.gov

Short-Term Application of Tocilizumab Following Myocardial Infarction

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Myocardial Infarction
Interventions
DRUG

Tocilizumab

162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)

DRUG

Placebo

Saline injection

Trial Locations (1)

39534

Keesler Medical Center, Keesler Air Force Base

All Listed Sponsors
lead

Keesler Air Force Base Medical Center

FED

NCT02419937 - Short-Term Application of Tocilizumab Following Myocardial Infarction | Biotech Hunter | Biotech Hunter